4/17
08:30 am
vtgn
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Low
Report
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
3/19
08:30 am
vtgn
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
Low
Report
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
3/4
08:30 am
vtgn
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
Medium
Report
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
2/20
08:30 am
vtgn
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
Low
Report
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
2/14
06:20 pm
vtgn
https://seekingalpha.com/article/4758658-vistagen-pherine-candidate-proof-of-concept-continues-with-fifth-indication [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4758658-vistagen-pherine-candidate-proof-of-concept-continues-with-fifth-indication [Seeking Alpha]
2/14
02:37 am
vtgn
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... [Yahoo! Finance]
Low
Report
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... [Yahoo! Finance]
2/13
04:55 pm
vtgn
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update [Yahoo! Finance]
Medium
Report
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update [Yahoo! Finance]
2/13
04:30 pm
vtgn
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Medium
Report
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
2/6
08:30 am
vtgn
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
Low
Report
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
2/5
08:30 am
vtgn
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Medium
Report
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain